Limitations, agreements, and source contact

Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer · Source last updated 2023-12-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

limitations And Caveats

description

This study terminated early due to weak accrual and therefore no inference is possible.

point Of Contact

email

Robert_Haddad@dfci.harvard.edu

organization

Dana-Farber Cancer Institute

phone

617.632.3090

title

Robert Haddad, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice